Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AARDVARK THERAPEUTICS, INC.

Aardvark Therapeutics, Inc. (NASDAQ: AARD)
Listen to this Section


$5.78
+0.0170 ( +0.30% ) 33.9K

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Market Data


Open $5.78
Previous Close $5.76
Volume 33.9K
Market Cap $104.50M
Day Range $5.58 - $5.96
52 Week Range $3.35 - $17.94
Shares Outstanding 21.82M
Change % +0.30%
Net Change ▲ 0.0170
Insider Ownership N/A
Exchange NASDAQ
SectorBasic Materials
IndustryPHARMACEUTICAL PREPARATIONS
IPO Year2025
CountryUnited States
UnderwriterMorgan Stanley, BofA Securities, Cantor Fitzgerald, RBC Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: 21,500.00

Date Type Amount Purchased Purchaser
2025-09-16 Buy 6500.00 Lee Tien-Li
2025-09-12 Buy 9000.00 Lee Tien-Li
2025-09-10 Buy 6000.00 Sun Nelson

SEC Filings


Form Type Description Pages Date
8-k 8K-related 11 Nov 13, 2025
10-q Quarterly Reports 72 Nov 13, 2025
8-k 8K-related 76 Nov 06, 2025
8-k 8K-related 17 Nov 04, 2025
4 Insider transactions 1 Oct 16, 2025
4 Insider transactions 1 Oct 16, 2025
8-k 8K-related 12 Oct 09, 2025
4 Insider transactions 1 Sep 16, 2025
4 Insider transactions 1 Sep 12, 2025
4 Insider transactions 1 Sep 10, 2025

Latest News